ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
The Use Of Anti-tnf Drugs In Rheumatic Disorders: Medical Education
Dr. Salih PAYb
aRomatoloji BD, GATA, ANKARA
TNF- is a proinflammatory cytokine, which plays a crucial role in the pathogenesis of rheumatoid arthritis and a number of other inflammatory diseases. Recently, anti-TNF drugs, which antagonize the biological activity of TNF- have started to be used in the treatment of rheumatological disorders. There are 3 anti-TNF drugs currently used in our country and throughout the world for this purpose. Of those, etanercept (Enbrel®) is a dimeric TNF receptor, and infliximab (Remicade®) and adalimumab (Humira®) are human-murine chimeric (75% human and 25% murine) and human monoclonal antibodies, respectively. In Turkey, infliximab was licensed for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn’s disease, etanercept for rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis and juvenile idiopathic arthritis and adalimumab only for rheumatoid arthritis. Although their anti-inflammatory activities are dependent on the blockade of TNF-α, they have different effects on the immune system and inflammation due to their different structures and physiological features, which determine both their clinical indications and side effects. As in all other drugs, side effects as well as clinical activity are very crucial issues.Keywords: TNFR-Fc fusion protein, infliximab, adalimumabTurkiye Klinikleri J Med Sci 2006, 26:430-440
|
|
|
|
|
